Tivozanib is a potent oral vascular endothelial growth factor receptor tyrosine kinase inhibitor indicated for the treatment of patients with relapsed or refractory advanced renal cell carcinoma. This… Read more













Tivozanib is a potent oral vascular endothelial growth factor receptor tyrosine kinase inhibitor indicated for the treatment of patients with relapsed or refractory advanced renal cell carcinoma. This category encompasses a comprehensive selection of Tivozanib reference standards, including the active pharmaceutical ingredient, its hydrochloride salt, and various related compounds essential for pharmaceutical research and development. Laboratories utilize these high-quality materials, which include pharmacopeial and non-pharmacopeial impurities, such as nitroso derivatives, for critical impurity profiling and method validation. Additionally, the inclusion of stable isotope labelled compounds, such as deuterium and 13C-labelled analogs, provides reliable internal standards for mass spectrometry-based bioanalytical studies. These compounds support robust analytical testing and quality control procedures, ensuring the accuracy and consistency of regulatory submissions throughout the drug development lifecycle.